🇺🇸 FDA
Patent

US 11202784

Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency

granted A61KA61K31/437A61K31/473

Quick answer

US patent 11202784 (Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency) held by Corcept Therapeutics Incorporated expires Mon Dec 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Corcept Therapeutics Incorporated
Grant date
Tue Dec 21 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61K, A61K31/437, A61K31/473, A61K31/513, A61K31/567